Hyperprolinemia Type II, also known as pyrroline-5-carboxylate reductase 1 deficiency, is a rare metabolic disorder characterized by elevated levels of proline in the blood and urine. This condition is caused by mutations in the PYCR1 gene, which is responsible for producing an enzyme called pyrroline-5-carboxylate reductase 1. The deficiency of this enzyme leads to the accumulation of proline, resulting in various symptoms and health complications.
One of the primary manifestations of Hyperprolinemia Type II is the presence of neurological symptoms. Individuals with this condition may experience intellectual disability, developmental delay, and learning difficulties. These cognitive impairments can range from mild to severe and may affect the individual's ability to learn, communicate, and perform daily tasks. Some affected individuals may also exhibit behavioral problems, such as attention deficit hyperactivity disorder (ADHD) or autism spectrum disorder (ASD).
Seizures are another common symptom of Hyperprolinemia Type II. These abnormal electrical activities in the brain can cause a wide range of symptoms, including convulsions, loss of consciousness, muscle spasms, and repetitive movements. Seizures can vary in frequency and severity among affected individuals, and they may require medical intervention to manage and control.
Some individuals with Hyperprolinemia Type II may exhibit facial dysmorphism, which refers to abnormal facial features. These features can include a prominent forehead, a broad nasal bridge, a long and flat philtrum (the area between the nose and upper lip), and a thin upper lip. While these facial characteristics are not specific to Hyperprolinemia Type II and can be found in other genetic conditions, their presence may raise suspicion for this disorder.
Connective tissue abnormalities are also observed in some individuals with Hyperprolinemia Type II. These abnormalities can manifest as joint hypermobility, which is the ability to extend joints beyond the normal range of motion. Affected individuals may have loose or flexible joints, which can lead to joint pain, instability, and an increased risk of joint dislocations.
In addition to the aforementioned symptoms, Hyperprolinemia Type II may present with other possible features, although they are less common. These can include low muscle tone (hypotonia), feeding difficulties in infancy, failure to thrive, short stature, and mild facial anomalies. It is important to note that the severity and combination of symptoms can vary widely among affected individuals, even within the same family.
Hyperprolinemia Type II is a rare metabolic disorder characterized by elevated levels of proline in the blood and urine. The symptoms of this condition primarily involve neurological manifestations, such as intellectual disability, developmental delay, and seizures. Facial dysmorphism and connective tissue abnormalities may also be present. While there is currently no cure for Hyperprolinemia Type II, early diagnosis and management of symptoms can help improve the quality of life for affected individuals.